Chen Yi-Chyan, Shen Yu-Chih, Hung Yi-Jen, Chou Chao-Ha, Yeh Chin-Bin, Perng Cheng-Hwang
Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
J Affect Disord. 2007 Nov;103(1-3):257-61. doi: 10.1016/j.jad.2007.01.023. Epub 2007 Feb 22.
To investigate the effects of antidepressants on glucose-insulin homeostasis, we provided homogenous situation and performed standard procedures to assess the interactions of antidepressants and glucose regulation during hospitalization.
Twenty-three non-diabetic depressed males were recruited and assigned to two groups based on the antidepressants received (maprotiline n=11, fluoxetine n=12). The severity of depression was evaluated using a 21-item Hamilton depression rating scale (HAM-D). Before and after the 4-week treatment, participants underwent 75-g oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIGT). Insulin sensitivity (SI), glucose effectiveness (SG), acute insulin response (AIR), and disposition index (DI) were estimated using minimal model method.
The HAM-D scores were reduced significantly (P<0.005) after antidepressant treatment. Following maprotiline treatment, the body weight and BMI were significantly increased (P=0.02). Individuals treated with maprotiline displayed a significantly increased AIR (3239+/-682 vs. 4698+/-597 pmol; P=0.04) during the FSIGT.
The sample size was limited. Furthermore, the study was conducted in the early phase of depression-treated course.
The results suggest that the beta-cell function is hyperbolic in order to offset the insulin resistance following maprotiline treatment. Our findings imply that norepinephrine reuptake inhibitor (NRI) antidepressants might attenuate insulin sensitivity.
为研究抗抑郁药对葡萄糖 - 胰岛素稳态的影响,我们提供了同质的情况,并在住院期间执行标准程序以评估抗抑郁药与葡萄糖调节之间的相互作用。
招募了23名非糖尿病男性抑郁症患者,并根据所服用的抗抑郁药将其分为两组(马普替林组n = 11,氟西汀组n = 12)。使用21项汉密尔顿抑郁量表(HAM-D)评估抑郁严重程度。在4周治疗前后,参与者接受了75克口服葡萄糖耐量试验(OGTT)和频繁采样静脉葡萄糖耐量试验(FSIGT)。使用最小模型法估计胰岛素敏感性(SI)、葡萄糖效能(SG)、急性胰岛素反应(AIR)和处置指数(DI)。
抗抑郁药治疗后HAM-D评分显著降低(P<0.005)。马普替林治疗后,体重和BMI显著增加(P = 0.02)。在FSIGT期间,接受马普替林治疗的个体显示AIR显著增加(3239±682 vs. 4698±597 pmol;P = 0.04)。
样本量有限。此外,该研究是在抑郁症治疗过程的早期阶段进行的。
结果表明,为抵消马普替林治疗后的胰岛素抵抗,β细胞功能呈双曲线变化。我们的研究结果表明,去甲肾上腺素再摄取抑制剂(NRI)抗抑郁药可能会减弱胰岛素敏感性。